AHRQ CDS Connect - Pilot Site Training for the Clinical Decision Support (CDS) Pain Management Summary

Presented by the CAMH Federally Funded Research and Development Center, operated by MITRE













Training Agenda

- Brief background on the CDS Connect project
- Evidence-based guidelines related to opioid prescribing and chronic pain management
- Overview of the Pain Management Summary
- How to access and use the Pain Management Summary "app"
- Demo of the app and its features
- Demo of the app in Epic Release
- Engaging patients with the Summary to facilitate shared decision making
- Evaluation of the Summary app
- Reporting concerns and sharing feedback on the app
- Final questions and closing

CDS Connect Background Information

CDS Connect Mission and Activities

Mission: Demonstrate a system that supports new evidence-based standards of care, codifies Clinical Decision Support (CDS) artifacts based on those standards using an interoperable, international data standard, and shares the resulting CDS capabilities via an accessible, webbased tool.


Activities:

- Repository: Design and build an online software "repository" for hosting and sharing new CDS artifacts (https://cds.ahrq.gov/cdsconnect)
- Authoring: Build a public facing, web-based CDS Authoring tool geared toward non-technical users (https://cds.ahrq.gov/cdsconnect/authoring)
- Artifacts: Identify and codify new CDS artifacts for care, initially in the domain of cholesterol management and now in the domain of chronic, non-malignant pain
- Pilot: Pilot CDS artifacts in a live, clinical setting
- Work Group: Convene external discussions focused on accelerating evidence into practice through CDS

Sponsor: Agency for Healthcare Research and Quality



CDS Connect Pilot: Timeline



The Pain Management Summary

CDC Guideline for Prescribing Opioids for Chronic Pain

- Non-pharmacologic & non-opioid therapies preferred
- Establish treatment goals with patients
- Assess and discuss risks and benefits
 - Prescribe naloxone if at high risk
- Prescribe immediate-release opioids
- Prescribe the lowest effective dose
- Monitor PDMP
 - ≤50 MME/day preferred
 - ≥90 MME/day is high risk
- Urine drug screening (prior to and annually)
- Avoid concurrent benzodiazepines
- Offer medication-assisted Tx (MAT) for OUD

GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN

IMPROVING PRACTICE THROUGH RECOMMENDATIONS

CDC's Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.

DETERMINING WHEN TO INITIATE OR CONTINUE OPIDIDS FOR CHRONIC PAIN

- Merpharmacologic therapy and nonopioid pharmacologic therapy are proformed for chemic pain. Climicians should consider opioid therapy only if expected benefits for both pain and function are enticipated to outweigh risks to the patient. If opioids are used, they should be combined with nonpharmacologic therapy, and nonopioid pharmacologic therapy, as appropriate.
- Before starting opioid therapy for chemic pain, clinicians should establish treatment goals with all patients, socioding realistic goals for pain and function, and should consider how opioid thorapy will be discontinued if benefits do not outweigh risks. Cânicians should continue opioid therapy only if there is clinically meaningful improvement in pain and function that outweight risks to patient safety.
- Before starting and periodically during opicid therapy, clinicians should discuss with potients known risks and soutistic benefits of uplood therapy and patient and clinician responsibilities for monoraine thorapy.

- CLINICAL REMINDERS
- Opinids are not first-line or routine therapy for chronic pain
- Establish and measure goals for pain and function
- Discuss besetts and risks and availability of nonepioid therapies with patient



" LEARN MORE I www.cdc.gov/drugevendose/prescribing/guideline.html

https://www.cdc.gov/drugoverdose/prescribing/guideline.html

Pain Management Summary Clinical Decision Support (CDS)

Pertinent Medical History

- Conditions associated with chronic pain
- Risk factors for opioid-related harms

Pain Assessments

- Wong-Baker FACES Rating Scale
- PEG & STarT Back Screening Tools
- Patient's goal for pain management

Historical treatments

- Opioid medications
- Non-opioid medications
- Non-pharmacologic treatments
- Stool softeners and laxatives

Risk Considerations

- MME amount
- Urine drug screen results
- Benzodiazepine medications
- Naloxone medications
- Risk screenings relevant to pain management
- PDMP access

Objectives:

- Display relevant data to inform pain management decisions
- Include concepts outlined in the CDC guideline
- Provide contextual notifications via flags
- Facilitate shared decision making

Be aware:

- The Summary does not display or provide notifications for all of the CDC recommendations
- The summary does not make treatment recommendations
- Clinicians are encouraged to use their medical knowledge and awareness of evidence-based guidelines to make the best decision for each patient

CDS Summary Section: Pertinent Medical History

- Conditions associated with chronic pain-
- Risk factors for opioid-related harms
 - Depression

Anxiety

Pulls active diagnoses from the Problem List for most Conditions

- Sleep-disordered breathing
- Renal dysfunction
- Hepatic Dysfunction
- Pregnancy
- Age >=65
- SUD*
- Suicide attempt*

Sample of included diagnoses

- 723 Cervical Spinal Stenosis
- 723.1 Cervicalgia
- 723.3 Cervicobrachial Syndrome
- 723.4 Brachial Neuritis NOS
- 723.5 Contracture Of Neck NOS
- 723.6 Panniculitis Affecting Neck
- 723.7 Ossification Cerv Lig
- 723.8 Cervical Syndrome NEC
- 723.9 Disorder Of Cervical Region NEC
- 724 Spinal Stenosis Nos
- 724.01 Spinal Stenosis Of Thoracic Region
- 724.02 Spinal Stenosis Of Lumbar Region
- 724.09 Spinal Stenosis NOS
- 724.1 Pain In Thoracic Spine
- 724.2 LBP [Low Back Pain]
- 724.3 Cotungo's Disease
- 724.4 Lumbosacral Neuritis NOS
- 724.5 Back Pain
- 724.6 Ankylosis Of Lumbosacral Joint
- 724.7 Disorder Of Coccyx NOS
- 724.79 Coccydynia
- 724.8 Ossification Of Posterior Longitudinal Ligament NOS
- 724.9 Ankylosis Of Spine NOS
- 729 Fibrositis NOS
- 729.1 Fibromyalgia
- 729.2 Neuralgia NOS

*Pulls *any* instance of SUD or suicide attempt (whether active or resolved) from Encounters or the Problem List

CDS Summary Section: Assessments and Treatments

Pain Assessments

- Pain intensity rating
 - Wong Baker FACES scale: 0-5 rating
- Multi-dimensional assessments
 - PEG include responses to each question and the total score
 - STarT Back Tool include the total score only

Historical treatments

- Opioid medications over the past 2 years
- Non-opioid medications over the past 2 years
- Non-pharmacologic treatments over the past 2 years
- Stool softeners and laxatives over the past 6 months

Pulls assessments completed over the past 2 years

Medications:

Pulls med orders and statements

Non-opioids include: ASA, APAP, NSAIDS, anticonvulsants, antidepressants, muscle relaxants, topical analgesics

Non-pharmacologic treatments:

Pulls referrals

Non-pharm treatments include: PT, acupuncture, electrotherapy, selfmanagement

CDS Summary Section: Risk Factors and Assessments

- MME amount most recent
- Urine drug screen results all within the past 1 year
- Benzodiazepine medications all within the past 2 years
- Naloxone medications ever prescribed
- Risk screenings relevant to pain management all within the past 1 year
 - Opioid Risk Tool, PHQ 2, PHQ 9, GAD-7, AUDIT, AUDIT-C, DAST-10
 - Alcohol one item screen
 - How many time in the past year have you had five or more drinks (men) or four or more drinks (women). 0=none, 1=1 or more
 - Drug one item screen
 - How many times in the past year have you used a recreational drug or used a prescription medication for nonmedical reasons? 0=none, 1=1 or more


SMART on FHIR Interface

Target Patient Population for the Summary

The Summary is intended for patients ≥ 18 yrs. old with:

- A condition associated with chronic pain
- An opioid medication entered in their record in the past 6 months
- An adjuvant analgesic entered in their record in the past 6 months

The Summary will display and populate for these patients




Take Notice


Per the CDC Guideline for Prescribing Opioids for Chronic Pain, the Summary is not intended for patients:

- Receiving end of life care (e.g., palliative care, hospice care)
- Undergoing active cancer treatment

since they have unique needs that require special consideration and treatment



Warning Message (when patient does not meet applicable criteria)




The Summary will NOT display or populate when the patient does not meet the outlined criteria

Additional Information within the Summary Interface

Flags

 Are intended to draw the clinicians eye to an entry of potential concern, based on CDC guidelines



Tooltips

- Provide additional information about why the entry was flagged

Information icons

Provide info on what data was pulled to populate the Summary and references, at times

URLs

To guidelines and additional references

more info

Numeric Pain Intensity Assessments

Demo of the Pain Management Summary App

Demo of App in Epic Release

Engaging Patients with the Summary Information

Premise: Transparency and knowledge is powerful. An activated patient will be more engaged in their care, improving their outcomes.

Level of patient engagement may depend upon:

- How much pain the patient is in
- Their relationship with the clinician
- Amount of time available

information available to help me help you to manage your pain"

"I'd like to share some of the

- "Here is how the answers that you provided about your pain and quality of life are displayed to inform how to manage you pain"
- "Managing pain is difficult. Let's make sure that our plan helps you and doesn't hurt you."

Value of sharing the summary information

- Provides a vehicle for discussion and shared decision making
- Provides an opportunity to identify errors in the patient record
- May shed new light on how assessment responses are being used

Evaluation of the Pain Management Summary

Objective metrics

- Reports based on data availability to populate the Pain Management Summary
 App and App usage
- Reported at pre-determined intervals (pre-pilot, during the pilot, and post-pilot)

Subjective feedback

- Midpoint touchpoint in mid July
- Focus groups at the end of the pilot period (around August 10th)
- Ad hoc touchpoints or email discussions are welcome at any time!
 - See contact info on the next slide
- If interested, thoughts captured in a Word document or scratchpad are welcome also

Back Up Slides

List of Flags Implemented in the Summary Interface - Part 1

- Risk Factors for Opioid-related Harms
 - Elements: Depression, Anxiety, Substance use disorder, suicide attempt, sleep-disordered breathing, renal dysfunction, hepatic dysfunction, pregnancy, >=65 years old.
 - Always flag if present: "Factor that may place the patient at risk for an opioid-related harm."

Historical Pain-related Treatments

- Opioid Medications
 - Elements: opioid medication statements and orders
 - Always flag if present: "Opioid medication"
- Non-Opioid Medications
 - Elements: non-opioid medication statements and orders
 - Flag if none are present: "Absence of non-opioid medications."
- Non-Pharmacologic Treatments
 - Elements: non-pharmacologic procedures
 - Flag if none are present: "Absence of non-pharmacologic treatments."
- Stool Softeners and Laxatives
 - Elements: Stool softeners/laxative medication statements and orders.
 - Flag if stool softeners are not present, but at least one opioid medication is present: "Absence of stool softener/laxative with presence of at least one opioid medication."

No information is flagged in the following sections:

- Conditions associated with chronic pain
- Pain and Risk Assessments

List of Flags Implemented in the Summary Interface - Part 2

Risk Considerations

- Most Recent MME
 - Elements: Morphine Milligram Equivalent (MME)
 - Flag if result is greater than or equal to 50: "Most recent MME assessment is 50+ MME/day."
- Urine Drug Screens
 - Elements: Urine drug screen
 - Flag if urine drug screen is not present and at least one opioid medication is present: "Absence of urine drug screen and at least one opioid medication."
- Benzodiazepine Medications
 - Elements: Benzodiazepine medication statements and orders.
 - Flag if there is at least one benzodiazepine medication and at least one opioid medication:
 "Benzodiazepine medication and at least one opioid medication."
 - Flag if there is at least one benzodiazepine medication: "Evidence of a benzodiazepine medication"
- Naloxone Medications
 - Elements: Naloxone medication statements and orders
 - Flag if naloxone medication is not present and most recent MME is greater than or equal to 50: "Absence
 of Naloxone medication and most recent MME assessment is 50+ MME/day."
 - Flag if one or more naloxone medication is present: "Evidence of Naloxone medication."